| [1] |
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin,2013,63(1):11-30.
|
| [2] |
Toi M, Ohashi Y, Seow A, et al. The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer[J].Jpn J Clin Oncol,2010,40 Suppl 1:i13-i18.
|
| [3] |
Chow LW, Yip AY, Ng EL. Prevention of oncological diseases: primary and secondary prevention[J]. Int J Biol Markers,2012,27(4):e337-e343.
|
| [4] |
Yip AY, Chu WP, Chow LW, et al. Methods of early detection: would clinical breast examination and breast ultrasonography be a good alternative to mammography? [J/CD]. Chin J Breast Dis (Electron Ed),2011,5(6):646-659.
|
| [5] |
Ng KK, Fung SY, Chow LW. Practice of breast selfexamination among high risk Chinese women in Hong Kong[J]. Chin Med J (Engl),2000,113(12):1100-1103.
|
| [6] |
Kachalia A, Mello MM. Breast cancer screening: conflicting guidelines and medicolegal risk[J]. JAMA, 2013, 309(24):2555-2556.
|
| [7] |
Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review[J]. Lancet,2012,380(9855):1778-1786.
|
| [8] |
Woolf SH, Harris R. The harms of screening: new attention to an old concern[J]. JAMA,2012,307(6):565-566.
|
| [9] |
Southey MC, Ramus SJ, Dowty JG, et al. Morphological predictors of BRCA1 germline mutations in young women with breast cancer[J]. Br J Cancer,2011,104(6):903-909.
|
| [10] |
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:a combined analysis of 22 studies[J]. Am J Hum Genet,2003,72(5):1117-1130.
|
| [11] |
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance[J]. J Clin Oncol,2007,25(11):1329-1333.
|
| [12] |
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study[J]. J Natl Cancer Inst,2005,97(22):1652-1662.
|
| [13] |
Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition[J]. J Clin Oncol,2002,20(15):3328-3343.
|
| [14] |
Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen,raloxifene, and aromatase inhibition for breast cancer risk reduction[J]. J Clin Oncol,2009,27(19):3235-3258.
|
| [15] |
Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial[J]. J Natl Cancer Inst,2007,99(4):283-290.
|
| [16] |
Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy[J]. J Natl Cancer Inst,2007,99(9):727-737.
|
| [17] |
Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial[J]. J Natl Cancer Inst, 2007, 99(4):272-282.
|
| [18] |
Lazzeroni M, Serrano D, Dunn BK, et al. Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug[J]. Breast Cancer Res, 2012,14(5):214.
|
| [19] |
Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation[J]. Breast Cancer Res Treat,2001,65(2):125-134.
|
| [20] |
Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women:results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation[J]. JAMA,1999,281(23):2189-2197.
|
| [21] |
Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene[J]. J Natl Cancer Inst,2004,96(23):1751-1761.
|
| [22] |
Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women[J]. N Engl J Med, 2006, 355(2):125-137.
|
| [23] |
Grady D, Cauley JA, Geiger MJ, et al. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk[J]. J Natl Cancer Inst, 2008, 100 (12):854-861.
|
| [24] |
Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually[J]. J Natl Cancer Inst,1989,81(24):1879-1886.
|
| [25] |
Gail MH, Costantino JP. Validating and improving models for projecting the absolute risk of breast cancer[J]. J Natl Cancer Inst,2001,93(5):334-335.
|
| [26] |
Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial[J]. JAMA,2006,295(23):2727-2741.
|
| [27] |
Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomised trial[J]. Lancet, 2002,359(9324):2131-2139.
|
| [28] |
Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer[J]. N Engl J Med,2003,349(19):1793-1802.
|
| [29] |
Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer[J]. N Engl J Med,2004,350(11):1081-1092.
|
| [30] |
Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women[J]. N Engl J Med,2011,364(25):2381-2391.
|
| [31] |
Barton MK. Exemestane is effective for the chemoprevention of breast cancer[J]. CA Cancer J Clin,2011,61(6):363-364.
|
| [32] |
Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole[J]. Expert Rev Anticancer Ther,2008,8(9):1377-1385.
|
| [33] |
Nelson HD,Smith ME,Griffin JC,et al. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force[J]. Ann Intern Med,2013,158(8):604-614.
|
| [34] |
Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci U S A, 2001,98(19):10869-10874.
|
| [35] |
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours[J]. Nature,2012,490(7418):61-70.
|
| [36] |
IARC working group on the evaluation of cancer-preventive agents. Weight control and physical activity [M]. Lyon:IARC,2002.
|
| [37] |
McCormack VA, Boffetta P. Today’s lifestyles, tomorrow’s cancers: trends in lifestyle risk factors for cancer in low-and middle-income countries[J]. Ann Oncol, 2011, 22(11):2349-2357.
|
| [38] |
Horn-Ross PL, Canchola AJ, Bernstein L, et al. Alcohol consumption and breast cancer risk among postmenopausal women following the cessation of hormone therapy use: the California Teachers Study[J]. Cancer Epidemiol Biomarkers Prev,2012,21(11):2006-2013.
|
| [39] |
McTiernan A. Behavioral risk factors in breast cancer: can risk be modified? [J]. Oncologist,2003,8(4):326-334.
|
| [40] |
Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy[J]. Lancet,2012,380(9838):219-229.
|
| [41] |
Voevodina O, Billich C, Arand B, et al. Association of Mediterranean diet, dietary supplements and alcohol consumption with breast density among women in South Germany: a cross-sectional study[J]. BMC Public Health,2013,13:203.
|
| [42] |
Conroy SM, Koga K, Woolcott CG, et al. Higher alcohol intake may modify the association between mammographic density and breast cancer: an analysis of three case-control studies[J]. Cancer Epidemiol,2012,36(5):458-460.
|
| [43] |
Maskarinec G, Takata Y, Pagano I, et al. Alcohol consumption and mammographic density in a multiethnic population[J]. Int J Cancer,2006,118(10):2579-2583.
|
| [44] |
Cabanes A, Pastor-Barriuso R, García-López M, et al.Alcohol, tobacco, and mammographic density: a populationbased study[J]. Breast Cancer Res Treat, 2011, 129(1):135-147.
|
| [45] |
National Cancer Institute. Breast cancer risk assessment tool[EB/OL].[2011-05-16]. http:/ /www.cancer.gov/bcrisktool/.
|
| [46] |
Bondy ML, Newman LA. Assessing breast cancer risk:evolution of the Gail Model[J]. J Natl Cancer Inst, 2006,98(17):1172-1173.
|
| [47] |
Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. Volume IX[M]. Lyon: IARC Press,2007.
|
| [48] |
Tam CY, Martin LJ, Hislop G, et al. Risk factors for breast cancer in postmenopausal Caucasian and Chinese-Canadian women[J]. Breast Cancer Res,2010,12(1):R2.
|
| [49] |
Chay WY, Ong WS, Tan PH, et al. Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28 104 Singapore women[J].Breast Cancer Res,2012,14(1):R19.
|
| [50] |
Criscitiello C. Tumor-associated antigens in breast cancer[J].Breast Care (Basel),2012,7(4):262-266.
|
| [51] |
Lazzeroni M, Serrano D. Potential use of vaccines in the primary prevention of breast cancer in high-risk patients[J].Breast Care (Basel),2012,7(4):281-287.
|
| [52] |
He JR, Tang LY, Yu DD, et al. Epstein-Barr virus and breast cancer: serological study in a high-incidence area of nasopharyngeal carcinoma[J]. Cancer Lett, 2011, 309(2):128-136.
|
| [53] |
Melana SM, Nepomnaschy I, Hasa J, et al. Detection of human mammary tumor virus proteins in human breast cancer cells[J]. J Virol Methods,2010,163(1):157-161.
|
| [54] |
Wang T, Chang P, Wang L, et al. The role of human papillomavirus infection in breast cancer[J]. Med Oncol,2012,29(1):48-55.
|